Ajax Therapeutics
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
275 Madison Ave Fl 39, New York, New Yor...Phone Number
(914) 204-6412Website
www.ajaxtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Ajax Therapeutics
Based out of New York City, Ajax Therapeutics is a biotechnology company with a focus on hematologic malignancies.Explore more
Popular SearchesAjax TherapeuticsAjax Therapeutics IncAjaxAjax Therapeutics and New YorkSIC Code 28,283NAICS Code 32,325Show moreAjax Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ajax Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Ajax Therapeutics
Check out if Ajax Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Ajax Therapeutics recently announced quarterly report
Ajax Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Ajax Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Ajax Therapeutics had a recent Job posting/layoffs
Check if Ajax Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Ajax Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Ajax Therapeutics
Compare insights from companies similar to Ajax Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ajax Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ajax Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ajax Therapeutics.
Ajax Therapeutics financials insights
Gather financial insights about Ajax Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Unspecified
$40M
2024
Series C
$95M
Ajax Therapeutics Tech Stack
A closer look at the technologies used by Ajax Therapeutics
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
New Hire
Executive Move
New Hire
Executive Move
Ajax Therapeutics News & Media
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion
Deal expands Lilly's oncology pipeline with experimental blood cancer drug.Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on its unique mode of binding JAK2, AJ1-11095 has the potential to deliver deeper and more...Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis
AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with myelofibrosis, previously treated with a Type I JAK2 inhibitor AJ1-11095 is a first-in-class Type II JAK2 inhibitor currently in a Phase 1 study for the treatment of patients with myelofibrosis, previously treated with a Type I JAK2 inhibitorAjax Therapeutics Presents Preclinical Data on Differentiated Efficacy Profile of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the American Society of Hematology Annual Meeting
– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and bone marrow fibrosis, key markers of disease modification –
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Ajax Therapeutics
Sign Up For FreeTo access detailed company insights
Based out of New York City, Ajax Therapeutics is a biotechnology company with a focus on hematologic malignancies.... Read More
